PSMD9 expression correlates with recurrence after radiotherapy in patients with cervical cancer

Köster,Frank; Sauer,Lisa; Hoellen,Friederike; Ribbat‑Idel,Julika; Bräutigam,Karen; Rody,Achim; Banz‑Jansen,Constanze

doi:10.3892/ol.2020.11622

PSMD9 expression correlates with recurrence after radiotherapy in patients with cervical cancer

Authors:
- Frank Köster
- Lisa Sauer
- Friederike Hoellen
- Julika Ribbat‑Idel
- Karen Bräutigam
- Achim Rody
- Constanze Banz‑Jansen
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, University of Lübeck and University Medical Center Schleswig‑Holstein, Campus Lübeck, D‑23538 Lübeck, Germany, Institute of Pathology, University of Lübeck and University Medical Center Schleswig‑Holstein, Campus Lübeck, D‑23538 Lübeck, Germany, Department of Gynecology and Obstetrics, Evangelisches Krankenhaus Bethel, D‑33617 Bielefeld, Germany
Published online on: May 14, 2020 https://doi.org/10.3892/ol.2020.11622
Pages: 581-588
Copyright: © Köster et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the current retrospective cohort study, the expression of the Proteasome 26S non-ATPase Subunit 9 (PSMD9) was investigated in 102 patients with cervical cancer. The rat homologue of PSMD9, Bridge‑1, was identified as a binding protein of the transcription factors PDX‑1 and E‑12 via its PDZ‑domain. The aim of the current study was to evaluate the prognostic or predictive value of PSMD9 expression as a biomarker for patients with cervical cancer. Tissue microarrays were constructed from formalin‑fixed paraffin‑embedded tissue specimens of cervical cancer and peritumoral stroma after hysterectomy and a Bridge‑1 antibody was used to perform immunohistochemistry. The immunoreactions were analyzed using an immunoreactive score, which evaluated the number of positive cells as well as their intensity of PSMD9 expression. A misinterpretation of statistically significant results after multiple testing was controlled by the false discovery rate correction using the algorithm of Benjamini and Hochberg. All tumor tissues and almost all peritumoral stroma tissues expressed PSMD9. The PSMD9 expression in tumor tissues was significantly higher compared with the peritumoral stroma. PSMD9 expression correlated significantly with the expression of the proliferation marker MIB‑1. Patients with stronger PSMD9 expression tended to exhibit a higher odds ratio for the recurrence of the disease in all patients (n=102) as well as in the subgroup of 47 patients having received a combined chemoradiotherapy following hysterectomy. In the group of 62 patients having that received radiotherapy following hysterectomy, which included the chemoradiotherapy patients, a higher PSMD9 expression significantly increased the odds for a recurrence to 1.983‑fold even after FDR correction (P=0.0304). In conclusion, PSMD9 was indicated to be overexpressed in tumor tissues and associated with tumor cell proliferation. Therefore, PSMD9 may be useful as a tumor marker. Furthermore, increased PSMD9 overexpression may be used to predict resistance against radiation.

View Figures

View References

1	World Health Organization: Cervical cancer. https://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/2019.
2	zur Hausen H: Papillomaviruses in the causation of human cancers-a brief historical account. Virology. 384:260–265. 2009. View Article : Google Scholar : PubMed/NCBI
3	Olusola P, Banerjee HN, Philley JV and Dasgupta S: Human papilloma virus-associated cervical cancer and health disparities. Cells. 8(pii): E6222019. View Article : Google Scholar : PubMed/NCBI
4	Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A and Colombo N; ESMO Guidelines Committee, : Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (Suppl 4):iv72–iv83. 2017. View Article : Google Scholar
5	Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF), . S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Langversion, 1.0, 2014, AWMF-Registernummer: 032/033OL. http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html2014.
6	Cohen PA, Jhingran A, Oaknin A and Denny L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
7	Thomas MK, Tsang SW, Yeung ML, Leung PS and Yao KM: The roles of the PDZ-containing proteins bridge-1 and PDZD2 in the regulation of insulin production and pancreatic beta-cell mass. Curr Protein Pept Sci. 10:30–36. 2009. View Article : Google Scholar : PubMed/NCBI
8	Langlands FE, Dodwell D, Hanby AM, Horgan K, Millican-Slater RA, Speirs V, Verghese ET, Smith L and Hughes TA: PSMD9 expression predicts radiotherapy response in breast cancer. Mol Cancer. 13:732014. View Article : Google Scholar : PubMed/NCBI
9	Banz-Jansen C, Munchow B, Diedrich K and Finas D: Bridge-1 is expressed in human breast carcinomas: Silencing of Bridge-1 decreases Smad2, Smad3 and Smad4 expression in MCF-7 cells, a human breast cancer cell line. Arch Gynecol Obstet. 284:1543–1549. 2011. View Article : Google Scholar : PubMed/NCBI
10	Banz C, Munchow B and Diedrich K: Bridge-1 is expressed in human granulosa cells and is involved in the activin A signaling cascade. Fertil Steril. 93:1349–1352. 2010. View Article : Google Scholar : PubMed/NCBI
11	Hoellen F, Waldmann A, Banz-Jansen C, Holtrich U, Karn T, Oberländer M, Habermann JK, Hörmann M, Köster F, Ribbat-Idel J, et al: Claudin-1 expression in cervical cancer. Mol Clin Oncol. 7:880–884. 2017. View Article : Google Scholar : PubMed/NCBI
12	Hoellen F, Waldmann A, Banz-Jansen C, Rody A, Heide M, Köster F, Ribbat-Idel J, Thorns C, Gebhard M, Oberländer M, et al: Expression of cyclooxygenase-2 in cervical cancer is associated with lymphovascular invasion. Oncol Lett. 12:2351–2356. 2016. View Article : Google Scholar : PubMed/NCBI
13	Oberländer M, Alkemade H, Bünger S, Ernst F, Thorns C, Braunschweig T and Habermann JK: A ‘waterfall’ transfer-based workflow for improved quality of tissue microarray construction and processing in breast cancer research. Pathol Oncol Res. 20:719–726. 2014. View Article : Google Scholar : PubMed/NCBI
14	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
15	Hemmerich W: Rechner zur Adjustierung des α-Niveaus: StatistikGuru. https://statistikguru.de/rechner/adjustierung-des-alphaniveaus.htmlJuly 21–2019
16	McBride WH, Iwamoto KS, Syljuasen R, Pervan M and Pajonk F: The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene. 22:5755–5773. 2003. View Article : Google Scholar : PubMed/NCBI
17	Kisser A and Zechmeister-Koss I: A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. BJOG. 122:64–70. 2015. View Article : Google Scholar : PubMed/NCBI
18	Yu L, Fei L, Liu X, Pi X, Wang L and Chen S: Application of p16/Ki-67 dual-staining cytology in cervical cancers. J Cancer. 10:2654–2660. 2019. View Article : Google Scholar : PubMed/NCBI
19	Sabeena S, Kuriakose S, Damodaran B, Ravishankar N and Arunkumar G: Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: A systematic review and meta-analysis. J Gynecol Oncol. 31:e202020. View Article : Google Scholar : PubMed/NCBI
20	Badaracco G, Savarese A, Micheli A, Rizzo C, Paolini F, Carosi M, Cutillo G, Vizza E, Arcangeli G and Venuti A: Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer. Oncol Rep. 23:1093–1099. 2010.PubMed/NCBI
21	Song YJ, Kim JY, Lee SK, Lim HS, Lim MC, Seo SS, Kang S, Lee DO and Park SY: Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer. Int J Cancer. 129:896–902. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yu MC, Austin RM, Lin J, Beck T, Beriwal S, Comerci JT, Edwards RP, Sukumvanich P, Kelley J and Olawaiye AB: The role of high-risk human papilloma virus testing in the surveillance of cervical cancer after treatment. Archives of pathology & laboratory medicine. 139:1437–1440. 2015. View Article : Google Scholar
23	Deng T, Feng Y, Zheng J, Huang Q and Liu J: Low initial human papillomavirus viral load may indicate worse prognosis in patients with cervical carcinoma treated with surgery. J Gynecol Oncol. 26:111–117. 2015. View Article : Google Scholar : PubMed/NCBI
24	Kamer S, Ren Q and Dicker AP: Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341). Arch Gynecol Obstet. 279:41–46. 2009. View Article : Google Scholar : PubMed/NCBI
25	Pajonk F, Grumann T and McBride WH: The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation. Neoplasia. 8:1037–1041. 2006. View Article : Google Scholar : PubMed/NCBI
26	Crawford LJ, Walker B and Irvine AE: Proteasome inhibitors in cancer therapy. J Cell Commun Signal. 5:101–110. 2011. View Article : Google Scholar : PubMed/NCBI
27	Harish M, Kannan S, Puttagunta S, Pradhan MR, Verma CS and Venkatraman P: A novel determinant of PSMD9 PDZ binding guides the evolution of the first generation of super binding peptides. Biochemistry. 58:3422–3433. 2019. View Article : Google Scholar : PubMed/NCBI
28	Han M, Wang H, Zhang HT and Han Z: Expression of TIP-1 confers radioresistance of malignant glioma cells. PLoS One. 7:e454022012. View Article : Google Scholar : PubMed/NCBI